THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR Russian patent published in 2022 - IPC A61K31/505 A61K31/4965 A61K31/5377 A61K45/06 A61P35/00 

FIELD: medicine; pharmaceutics.

SUBSTANCE: group of inventions relates to the field of medicine and pharmaceutics, in particular for the treatment of KRAS-mutant non-small cell lung cancer (hereinafter – NSCLC), BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (hereinafter – CRC) and KRAS-mutant ovarian cancer. For this purpose, a pharmaceutical combination is developed, containing CRAF inhibitor, which is a compound A of N-(3-(2-(2- hydroxyethoxy)-6-morpholinopyridine-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide or its pharmaceutically acceptable salt, and ERK inhibitor, which is a compound B of 4-(3-amino-6-((1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl)pyrazin-2-yl)-N-((S)-1-(3-bromo-5- fluorophenyl)-2-(methylamino)ethyl)-2-fluorobenzamide or its pharmaceutically acceptable salt. A pharmaceutical composition, the use of a pharmaceutical combination, and a treatment method are also disclosed.

EFFECT: group of inventions provides the creation of a combination of a compound A and a compound B, the combination of which will optimize the suppression of signal transmission by means of MAPK in KRAS- and BRAF-mutant NSCLC; this combination may also contribute to the prevention of occurrence of the resistance to a combination of BRAF and MEK (mitogen-activated protein kinase) inhibitors in BRAFV600E-mutant NSCLC.

12 cl, 3 dwg, 6 tbl, 6 ex